As per the agreement, Flamel Technologies will supply Coreg CR microparticles for GSK over a period of many years for assured minimum payments.
Flamel CEO Stephen H Willard said the new supply agreement would provide the company and its shareholders with higher margins and greater certainty.
"We believe that this agreement further strengthens our ability to develop both of our best-in-class drug delivery platforms," Willard added.